浅析奈玛特韦片/利托那韦片组合包装治疗新型冠状病毒感染的研究进展  

Research Progress in the Treatment of COVID-19 with Nirmatrelvir Tablets/Ritonavir Tablets (Co-Packaged)

作　　者：王维波 宁金堂 田明忠 周小明 WANG Wei-bo;NING Jin-tang;TIANMing-zhong;ZHOU Xiao-ming(Department of Pharmacy,Dongying People's Hospital,Dongying 257091,China;Department of Eugenics and Genetics,Dongying People's Hospital,Dongying 257091,China;Department of Scientific Research,Shandong First Medical University affiliated Provincial Hospital,Jinan 250021,China)

机构地区：[1]东营市人民医院药学部,东营257091 [2]东营市人民医院优生遗传科,东营257091 [3]山东第一医科大学附属省立医院科研部,济南250021

出　　处：《中国合理用药探索》2023年第9期8-12,共5页Chinese Journal of Rational Drug Use

基　　金：山东省重点研发计划(2022RZA04019);山东省医药卫生科技发展计划(202215020469)。

摘　　要：奈玛特韦片/利托那韦片组合包装是一种抗新型冠状病毒感染(COVID-19)药物,本文通过查阅近年来国内外相关文献进行整理和归纳,探讨并分析奈玛特韦片/利托那韦片组合包装的药学特性、适应症、药物相互作用、特殊人群用药安全性等临床应用情况,为临床合理用药提供参考。The nirmatrelvir tablets/ritonavir tablets(co-packaged)is an anti-COVID-19 drug.This article reviewed the Chinese and overseas relevant literatures published in recent years.These literatures were sorted out and summarized,discussed and analyzed from the aspects of the pharmaceutical characteristics,indications,drug interactions,drug safety in special populations and other clinical applications of the nirmatrelvir tablets/ritonavir tablets(co-packaged),to provide reference for clinical rational drug use.

关 键 词：新型冠状病毒感染 奈玛特韦片/利托那韦片组合包装 药学特性 特殊人群 合理用药 

分 类 号：R978.7[医药卫生—药品]